Literature DB >> 9541941

[Prognostic factors of prostatic carcinoma].

B Helpap1.   

Abstract

The histological classification or typing of prostate carcinoma combined with histological grading according to Gleason or WHO with nucleolar subgrading are the most important prognostic factors in carcinoma of the prostate. Prostatic cancer is the most common malignancy in adult males and is the second-most-common cause of cancer death in the USA. The histological Gleason grade may be reduced if only a small amount of tumor tissue is present in the core needle biopsy, in contrast to the combined histological and cytological grading according to WHO with nucleolar subgrading. When there is sufficient carcinomatous tissue in the core needle biopsy, there is no difference from that in radical prostatectomy tissue, because most cases of prostatic carcinoma are highly malignant. DNA cytometry, immunohistochemical analysis with Ki67/Mib1 or molecular pathological studies with the tumor suppressor gene p53 or apoptosis suppressing oncoprotein bcl2 and the density of blood capillaries may be helpful as additional prognostic factors, but only together with the results of the primary histological section. For comparison of grading results with the international literature both grading systems should be used according to Gleason and WHO with nucleolar subgrading.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541941     DOI: 10.1007/s002920050253

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  3 in total

1.  The effect of Rapid Access Prostate Clinics on the outcomes of Gleason 7 prostate cancer: does earlier diagnosis lead to better outcomes?

Authors:  M P Broe; J C Forde; M S Inder; D J Galvin; D W Mulvin; D M Quinlan
Journal:  Ir J Med Sci       Date:  2017-03-09       Impact factor: 1.568

2.  [Documentation quality of histopathology reports of prostate needle biopsies: a snapshot].

Authors:  S Biesterfeld
Journal:  Urologe A       Date:  2014-11       Impact factor: 0.639

3.  [Optimized standards for prostate biopsy].

Authors:  B Wullich; S Füssel; R Grobholz
Journal:  Urologe A       Date:  2007-06       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.